COMPASS Pathways plc
CMPS•NASDAQ•Healthcare•Medical Care Facilities

About COMPASS Pathways

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Company Information

SectorHealthcare
IndustryMedical Care Facilities
CEOKabir Nath
Founded2020
IPO DateSeptember 18, 2020
Employees166
CountryUnited Kingdom
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitecompasspathways.com
Address
33 Broadwick Street London, W1F 0DQ United Kingdom

Corporate Identifiers

CIK0001816590
CUSIP20451W101
ISINUS20451W1018
SIC2834

Leadership Team & Key Executives

Kabir Kumar Nath M.A., M.B.A.
Chief Executive Officer and Director
Teri Loxam M.B.A.
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Dr. Guy Goodwin
Chief Medical Officer
Dr. Greg Ryslik Ph.D.
Chief Technology Officer
Stephen D. Schultz
Senior Vice President of Investor Relations
Anne Benedict
Chief People Officer
Lars Christian Wilde
Senior Advisor
Dr. Susan C. Stansfield Ph.D.
Advisor
Dr. Michael Gold M.D., M.Sc.
Chief Research and Development Officer
Lori Englebert M.B.A.
Chief Commercial Officer